NasdaqGM - Nasdaq Real Time Price USD

Sera Prognostics, Inc. (SERA)

1.7100

-0.0700

(-3.93%)

At close: June 13 at 4:00:00 PM EDT

1.6830

-0.03

(-1.58%)

After hours: June 13 at 5:16:58 PM EDT

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 3 days ago

SERA
-3.93%
After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)

Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 15 days ago

SERA
-3.93%
SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that members of the Sera team will participate in the following upcoming investor conferences:

PR Newswire 15 days ago

SERA
-3.93%
SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss the company's latest achievements.

PR Newswire 30 days ago

SERA
-3.93%
Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround

Sera Prognostics (SERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

SERA
-3.93%
SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. Anderson has a proven track record of driving business growth and enhancing sales s

PR Newswire last month

SERA
-3.93%
Sera Prognostics Inc (SERA) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Sera Prognostics Inc (SERA) reports revenue growth and strategic initiatives, while navigating increased expenses and awareness challenges.

GuruFocus.com last month

SERA
-3.93%
Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates

Sera Prognostics (SERA) delivered earnings and revenue surprises of 16.67% and 62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

SERA
-3.93%
SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025.

PR Newswire last month

SERA
-3.93%
Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Eastern Time

PR Newswire last month

SERA
-3.93%
Sera Prognostics Full Year 2024 Earnings: Misses Expectations

Sera Prognostics ( NASDAQ:SERA ) Full Year 2024 Results Key Financial Results Net loss: US$32.9m (loss narrowed by 9.2...

Simply Wall St. 2 months ago

SERA
-3.93%
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates

Sera Prognostics (SERA) delivered earnings and revenue surprises of -8.70% and 20%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

SERA
-3.93%
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as pa

PR Newswire 2 months ago

QTRX

SERA
-3.93%

EXAS
SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024.

PR Newswire 2 months ago

SERA
-3.93%
Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. Easter

PR Newswire 3 months ago

SERA
-3.93%
US Penny Stocks To Watch In February 2025

As the U.S. stock market grapples with mixed performances and attempts to recover from recent downturns, investors are increasingly looking for opportunities that might not be immediately obvious among the major indices. Penny stocks, often associated with smaller or newer companies, continue to capture attention due to their potential for growth and affordability. Despite being considered a relic of past market eras, these stocks can offer compelling opportunities when backed by strong...

Simply Wall St. 3 months ago

FTEK

SERA
-3.93%

VFF
Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements.

PR Newswire 3 months ago

SERA
-3.93%
Sera Prognostics Announces Pricing of $50 Million Public Offering

Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its

PR Newswire 3 months ago

SERA
-3.93%
Sera Prognostics Announces Proposed Public Offering

Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock. In addition, Sera intends to grant the un

PR Newswire 3 months ago

SERA
-3.93%
Sera Prognostics to Host Virtual R&D Day on January 31

Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. PT. This date was changed from the prior planned date of the event due to scheduling conflicts.

PR Newswire 4 months ago

SERA
-3.93%

Performance Overview

Return	SERA	S&P 500 (^GSPC)
YTD	-78.99%	+1.62%
1-Year	-78.73%	+10.00%
3-Year	+42.50%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sera Prognostics, Inc. (SERA)

We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully

After Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)

SERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE

Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround

SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER

Sera Prognostics Inc (SERA) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic ...

Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates

SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025

Sera Prognostics Full Year 2024 Earnings: Misses Expectations

Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS

Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025

US Penny Stocks To Watch In February 2025

Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference

Sera Prognostics Announces Pricing of $50 Million Public Offering

Sera Prognostics Announces Proposed Public Offering

Sera Prognostics to Host Virtual R&D Day on January 31

Performance Overview